RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q3 2019
Top Holdings60 positions
Rocket Pharmaceuticals Inc | 16.6M | $192.5M | 11.4% | $17.46 | -32.92% | 3 qtrssince 2019-Q1 | Unchanged 0 |
Alnylam Pharmaceuticals Inc | 1.8M | $142.2M | 8.5% | $80.50 | +0.74% | 3 qtrssince 2019-Q1 | Decreased 0 |
PTC Therapeutics Inc | 3.7M | $123.5M | 7.3% | $38.47 | -10.01% | 3 qtrssince 2019-Q1 | Increased 68 |
Dicerna Pharmaceuticals Inc | 6.2M | $89.1M | 5.3% | — | — | 3 qtrssince 2019-Q1 | Increased 58 |
Bristol-Myers Squibb Co | 1.6M | $79.4M | 4.7% | $36.66 | +7.20% | 3 qtrssince 2019-Q1 | Increased 54 |
STOKE THERAPEUTICS INC | 3.4M | $69.4M | 4.1% | $29.17 | -29.62% | 2 qtrssince 2019-Q2 | Unchanged 0 |
MILESTONE PHARMACEUTICALS IN | 3.5M | $63.8M | 3.8% | $27.15 | -30.39% | 2 qtrssince 2019-Q2 | Unchanged 0 |
Zimmer Biomet Holdings Inc | 403,000 | $55.3M | 3.3% | $123.82 | 0.00% | 1 qtr | New 81 |
Masimo Corp | 371,155 | $55.2M | 3.3% | $138.53 | +5.84% | 3 qtrssince 2019-Q1 | Decreased 0 |
Sarepta Therapeutics Inc | 724,311 | $54.6M | 3.2% | $123.90 | -39.47% | 3 qtrssince 2019-Q1 | Increased 64 |
ACHILLION PHARMACEUTICALS IN | 13.9M | $49.9M | 3.0% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 |
Mirati Therapeutics Inc | 592,776 | $46.2M | 2.7% | — | — | 3 qtrssince 2019-Q1 | Increased 81 |
| 2.4M | $44.3M | 2.6% | — | — | 3 qtrssince 2019-Q1 | Increased 59 | |
AXONICS INC | 1.5M | $41.3M | 2.5% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 |
Vericel Corp | 2.6M | $40.1M | 2.4% | $17.53 | -14.63% | 3 qtrssince 2019-Q1 | Increased 50 |
ESTABLISHMENT LABS HLDGS INC | 2M | $38.6M | 2.3% | $23.06 | -19.51% | 3 qtrssince 2019-Q1 | Increased 54 |
MYOKARDIA INC | 725,025 | $37.8M | 2.2% | — | — | 3 qtrssince 2019-Q1 | Increased 50 |
Adverum Biotechnologies Inc | 6.3M | $34.2M | 2.0% | — | — | — | Decreased 0 |
TRANSLATE BIO INC | 3.1M | $31.2M | 1.9% | — | — | 3 qtrssince 2019-Q1 | Increased 57 |
BELLUS Health Inc | 4.2M | $26.9M | 1.6% | — | — | 1 qtr | New 66 |
RTW INVESTMENTS, LP manages $1.7B across 60 positions as of Q3 2019. Top holdings: RCKT (11.4%), ALNY (8.5%), PTCT (7.3%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
Active quarter - 15 new positions, 7 exits, 26 increased. Top move: ZBH (NEW, conviction 81). Portfolio: $1.7B across 60 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR